Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Determining serum levels of IL-10 and IL-17 in patients with low back pain caused by lumbar disc degeneration.

< BACK TO ARCHIVE


2020 Aug 19


Infect Disord Drug Targets


http://www.ncbi.nlm.nih.gov/pubmed/32819250?dopt=Abstract

Determining serum levels of IL-10 and IL-17 in patients with low back pain caused by lumbar disc degeneration.

Authors

Determining serum levels of IL-10 and IL-17 in patients with low back pain caused by lumbar disc degeneration.
Banimostafavi E S, Fakhar M, Abediankenari S, Alizadeh-Navaei R, Mehdipour K, Omrani-Nava V, Majidi H
Infect Disord Drug Targets. 2020 Aug 19.
PMID: 32819250.

Abstract

Low Back pain (LBP) is a common health problem that affects different aspects of a person's life. Degeneration of the intervertebral disc is a major cause of LBP. Interleukin-17 (IL-17) is a pro-inflammatory cytokine. In contrast, interleukin-10 (IL-10) prevents the occurrence of immune over-stimulation by inhibiting inflammation. The purpose of this study was to evaluate the serum levels of these cytokines in LBP patients and in the control group.
Read This Paper